ES2724232T3 - Procedimientos de detección de células tumorales circulantes positivas para 5T4 y procedimientos de diagnóstico de cáncer positivo para 5T4 en un sujeto mamífero - Google Patents

Procedimientos de detección de células tumorales circulantes positivas para 5T4 y procedimientos de diagnóstico de cáncer positivo para 5T4 en un sujeto mamífero Download PDF

Info

Publication number
ES2724232T3
ES2724232T3 ES13708526T ES13708526T ES2724232T3 ES 2724232 T3 ES2724232 T3 ES 2724232T3 ES 13708526 T ES13708526 T ES 13708526T ES 13708526 T ES13708526 T ES 13708526T ES 2724232 T3 ES2724232 T3 ES 2724232T3
Authority
ES
Spain
Prior art keywords
marker
cells
blood sample
positive
circulating tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13708526T
Other languages
English (en)
Spanish (es)
Inventor
Hans-Peter Gerber
Dena Marrinucci
Steven Pirie-Shepherd
Eric Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Epic Sciences Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Epic Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL, Epic Sciences Inc filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2724232T3 publication Critical patent/ES2724232T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G01N33/575—
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
ES13708526T 2012-01-24 2013-01-22 Procedimientos de detección de células tumorales circulantes positivas para 5T4 y procedimientos de diagnóstico de cáncer positivo para 5T4 en un sujeto mamífero Active ES2724232T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261590066P 2012-01-24 2012-01-24
US201361753665P 2013-01-17 2013-01-17
PCT/IB2013/050547 WO2013111054A1 (en) 2012-01-24 2013-01-22 Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject

Publications (1)

Publication Number Publication Date
ES2724232T3 true ES2724232T3 (es) 2019-09-09

Family

ID=47844410

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13708526T Active ES2724232T3 (es) 2012-01-24 2013-01-22 Procedimientos de detección de células tumorales circulantes positivas para 5T4 y procedimientos de diagnóstico de cáncer positivo para 5T4 en un sujeto mamífero

Country Status (14)

Country Link
US (1) US10254286B2 (enExample)
EP (1) EP2807485B1 (enExample)
JP (1) JP6254951B2 (enExample)
KR (1) KR101716555B1 (enExample)
CN (1) CN104094116B (enExample)
AU (2) AU2013213301A1 (enExample)
BR (1) BR112014018192A8 (enExample)
CA (1) CA2861437C (enExample)
ES (1) ES2724232T3 (enExample)
IL (1) IL233543B (enExample)
IN (1) IN2014DN07019A (enExample)
MX (1) MX361058B (enExample)
RU (1) RU2646498C2 (enExample)
WO (1) WO2013111054A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2803804B2 (ja) 1992-08-21 1998-09-24 株式会社長澤製作所 ボタン錠
AU2010310688A1 (en) 2009-10-21 2012-05-17 Epic Sciences, Inc. Method of using non-rare cells to detect rare cells
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EA201691352A1 (ru) * 2013-12-30 2016-11-30 Дзе Скриппс Рисерч Инститьют Диагностика рака легкого с помощью циркулирующих опухолевых клеток
WO2015112955A1 (en) 2014-01-27 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
US10545151B2 (en) * 2014-02-21 2020-01-28 Epic Sciences, Inc. Methods for analyzing rare circulating cells
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
EA201692223A1 (ru) * 2014-05-09 2017-04-28 Дзе Скриппс Рисерч Инститьют Композиции и способы жидкостной биопсии меланомы
US10871491B2 (en) * 2014-08-25 2020-12-22 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
CN113552350B (zh) * 2015-04-21 2024-10-11 基因泰克公司 用于前列腺癌分析的组合物和方法
CN114480574A (zh) * 2015-11-06 2022-05-13 文塔纳医疗系统公司 代表性诊断
KR102478639B1 (ko) 2016-02-23 2022-12-19 노을 주식회사 표지 물질을 저장하는 패치, 이를 이용하는 조직 진단 방법 및 장치
US10371610B2 (en) 2016-02-23 2019-08-06 Noul Co., Ltd. Contact-type patch, staining method using the same, and manufacturing method thereof
KR102406596B1 (ko) * 2016-02-23 2022-06-10 노을 주식회사 패치를 이용하는 ctc 진단 방법 및 장치
KR102045068B1 (ko) * 2016-02-23 2019-11-15 노을 주식회사 중합 효소 연쇄 반응 패치, 이를 이용하는 진단 방법 및 장치
KR20170099738A (ko) 2016-02-23 2017-09-01 노을 주식회사 접촉식 염색 패치 및 그 제조 방법
WO2018184966A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
WO2019005902A1 (en) * 2017-06-27 2019-01-03 Qcdx, Llc SYSTEM AND METHODS FOR DIAGNOSING QUANTITATIVE LIQUID BIOPSY
CN107918013A (zh) * 2017-09-25 2018-04-17 浙江天科高新技术发展有限公司 化学发光酶免测定循环肿瘤细胞中K‑Ras蛋白的方法及试剂盒
JP7678424B2 (ja) 2018-05-10 2025-05-16 学校法人順天堂 画像解析方法、装置、コンピュータプログラム、及び深層学習アルゴリズムの生成方法
US20220002429A1 (en) * 2018-10-24 2022-01-06 Northwestern University Tumor cell aggregation inhibitors' for treating cancer
JP7381003B2 (ja) * 2019-04-26 2023-11-15 学校法人順天堂 疾患解析を支援する方法、装置、及びコンピュータプログラム、並びにコンピュータアルゴリズムを訓練する方法、装置、及びプログラム
WO2023107566A1 (en) 2021-12-07 2023-06-15 Epic Sciences, Inc. Enhanced characterization of breast cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
EP0336562B1 (en) 1988-03-04 1995-06-14 Cancer Research Campaign Technology Ltd. Improvements relating to antigens
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
IL132596A0 (en) 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
AU1290001A (en) 1999-11-18 2001-05-30 Oxford Biomedica (Uk) Limited Antibodies
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US7305112B2 (en) 2002-10-15 2007-12-04 The Scripps Research Institute Method of converting rare cell scanner image coordinates to microscope coordinates using reticle marks on a sample media
RU2007108716A (ru) * 2004-09-10 2008-10-20 Вайет (Us) Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином
WO2007089911A2 (en) * 2006-01-30 2007-08-09 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
TWI421257B (zh) 2006-03-10 2014-01-01 Wyeth Corp 抗５ｔ４抗體及其用途
WO2008131048A2 (en) 2007-04-16 2008-10-30 Cellpoint Diagnotics, Inc. Devices and methods for diagnosing, prognosing, or theranosing a condition by enriching rare cells
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
CN102414562B (zh) 2009-03-24 2019-05-07 生物概念股份有限公司 细胞捕获和分析的装置和方法
JP5788863B2 (ja) 2009-03-27 2015-10-07 ワイス・エルエルシー 腫瘍開始細胞およびその使用方法
JP2013504064A (ja) 2009-09-03 2013-02-04 ザ スクリプス リサーチ インスティチュート 循環腫瘍細胞を分類する方法
AU2010310688A1 (en) 2009-10-21 2012-05-17 Epic Sciences, Inc. Method of using non-rare cells to detect rare cells
EP2556172A4 (en) * 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASES
DK2591363T3 (en) 2010-07-07 2017-12-11 Univ Michigan Regents DIAGNOSIS AND TREATMENT OF BREAST CANCER
BR112013025186A2 (pt) 2011-04-01 2018-09-11 Wyeth Llc conjugados de anticorpo-fármaco

Also Published As

Publication number Publication date
US10254286B2 (en) 2019-04-09
EP2807485B1 (en) 2019-03-13
AU2018220154A1 (en) 2018-09-13
BR112014018192A8 (pt) 2021-03-02
KR101716555B1 (ko) 2017-03-14
MX2014008928A (es) 2014-10-24
RU2014127474A (ru) 2016-03-20
KR20140100580A (ko) 2014-08-14
IL233543A0 (en) 2014-08-31
JP6254951B2 (ja) 2017-12-27
CN104094116B (zh) 2017-05-31
RU2646498C2 (ru) 2018-03-05
AU2013213301A1 (en) 2014-07-17
IL233543B (en) 2018-02-28
CA2861437C (en) 2018-08-21
EP2807485A1 (en) 2014-12-03
MX361058B (es) 2018-11-23
CN104094116A (zh) 2014-10-08
HK1202923A1 (en) 2015-10-09
US20150017661A1 (en) 2015-01-15
JP2015507190A (ja) 2015-03-05
IN2014DN07019A (enExample) 2015-04-10
CA2861437A1 (en) 2013-08-01
WO2013111054A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
ES2724232T3 (es) Procedimientos de detección de células tumorales circulantes positivas para 5T4 y procedimientos de diagnóstico de cáncer positivo para 5T4 en un sujeto mamífero
Marrinucci et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers
ES2661735T3 (es) Método para usar células no raras para detectar células raras
ES2420834T3 (es) Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero
ES2397971T3 (es) Ensayo de células tumorales circulantes
KR101604649B1 (ko) 혈액 내 순환 흑색종 세포의 자동화된 계산 및 특징화
Marrinucci et al. Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type
Tura et al. Identification of circulating melanoma cells in uveal melanoma patients by dual-marker immunoenrichment
US10823736B2 (en) Method of assessing disease condition of cancer
MX2014006884A (es) Aparato, sistema y metodo para identificar celulas tumorales circulantes.
WO2000026666A2 (en) Multiple marker characterization of single cells
CN101606060A (zh) 细胞图像的归类方法
US20180267046A1 (en) Methods for diagnosing and treating cancer
Yin et al. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium
ES2939298T3 (es) Combinación de marcadores para el diagnóstico del cáncer
RU2571821C2 (ru) Способ выявления циркулирующих опухолевых клеток, микроэмбол и апоптотических телец в крови больных раком легкого человека
US20250208138A1 (en) Method of isolating and analyzing circulating tumor cells
ES2356738T3 (es) Células tumorales circulantes (ctc): evaluación temprana del tiempo de evolución, de la supervivencia y la respuesta a la terapia en pacientes con cáncer metastásico.
HK1202923B (en) Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject
Cheema Pancreatic Tumor Cell Capture via Dendrimer-Mediated Multivalent Binding and Antibody Cocktail
JP2024512415A (ja) 小細胞肺がんおよび他の神経内分泌がんを処置するための方法
WO2025137394A1 (en) Using extracellular vesicles to assess treatment efficacy of antibody-drug conjugate (adc) therapies
Smerage et al. SECTION II: MOLECULAR AND CELLULAR MARKERS OF PROGNOSIS